Unknown

Dataset Information

0

Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.


ABSTRACT: In recent years, CRISPR (clustered regularly interspaced short palindromic repeat)/Cas (CRISPR-associated) genome editing systems have become one of the most robust platforms in basic biomedical research and therapeutic applications. To date, efficient in vivo delivery of the CRISPR/Cas9 system to the targeted cells remains a challenge. Although viral vectors have been widely used in the delivery of the CRISPR/Cas9 system in vitro and in vivo, their fundamental shortcomings, such as the risk of carcinogenesis, limited insertion size, immune responses and difficulty in large-scale production, severely limit their further applications. Alternative non-viral delivery systems for CRISPR/Cas9 are urgently needed. With the rapid development of non-viral vectors, lipid- or polymer-based nanocarriers have shown great potential for CRISPR/Cas9 delivery. In this review, we analyze the pros and cons of delivering CRISPR/Cas9 systems in the form of plasmid, mRNA, or protein and then discuss the limitations and challenges of CRISPR/Cas9-based genome editing. Furthermore, current non-viral vectors that have been applied for CRISPR/Cas9 delivery in vitro and in vivo are outlined in details. Finally, critical obstacles for non-viral delivery of CRISPR/Cas9 system are highlighted and promising strategies to overcome these barriers are proposed.

SUBMITTER: Li L 

PROVIDER: S-EPMC5944364 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.

Li Ling L   Hu Shuo S   Chen Xiaoyuan X  

Biomaterials 20180418


In recent years, CRISPR (clustered regularly interspaced short palindromic repeat)/Cas (CRISPR-associated) genome editing systems have become one of the most robust platforms in basic biomedical research and therapeutic applications. To date, efficient in vivo delivery of the CRISPR/Cas9 system to the targeted cells remains a challenge. Although viral vectors have been widely used in the delivery of the CRISPR/Cas9 system in vitro and in vivo, their fundamental shortcomings, such as the risk of  ...[more]

Similar Datasets

| S-EPMC9013665 | biostudies-literature
| S-EPMC7067791 | biostudies-literature
| S-EPMC6398936 | biostudies-literature
| S-EPMC10568484 | biostudies-literature
| S-EPMC7738854 | biostudies-literature
| S-EPMC6764340 | biostudies-literature
| S-EPMC7922307 | biostudies-literature
| S-EPMC9176214 | biostudies-literature
| S-EPMC7709491 | biostudies-literature
| S-EPMC7766488 | biostudies-literature